NCT02650986 - Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 14, 2017

Primary Completion Date

March 4, 2021

Study Completion Date

July 14, 2032

Conditions

Advanced Fallopian Tube CarcinomaAdvanced Malignant Solid NeoplasmAdvanced MelanomaAdvanced Ovarian CarcinomaAdvanced Primary Peritoneal CarcinomaAdvanced Synovial SarcomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Fallopian Tube CarcinomaMetastatic MelanomaMetastatic Ovarian CarcinomaMetastatic Primary Peritoneal CarcinomaMetastatic Synovial SarcomaPathologic Stage III Cutaneous Melanoma AJCC v8Pathologic Stage IIIA Cutaneous Melanoma AJCC v8Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8Pathologic Stage IV Cutaneous Melanoma AJCC v8Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaStage III Fallopian Tube Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Primary Peritoneal Cancer AJCC v8Stage IIIA Fallopian Tube Cancer AJCC v8Stage IIIA Ovarian Cancer AJCC v8Stage IIIA Primary Peritoneal Cancer AJCC v8Stage IIIA1 Fallopian Tube Cancer AJCC v8Stage IIIA1 Ovarian Cancer AJCC v8Stage IIIA2 Fallopian Tube Cancer AJCC v8Stage IIIA2 Ovarian Cancer AJCC v8Stage IIIB Fallopian Tube Cancer AJCC v8Stage IIIB Ovarian Cancer AJCC v8Stage IIIB Primary Peritoneal Cancer AJCC v8Stage IIIC Fallopian Tube Cancer AJCC v8Stage IIIC Ovarian Cancer AJCC v8Stage IIIC Primary Peritoneal Cancer AJCC v8Stage IV Fallopian Tube Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IV Primary Peritoneal Cancer AJCC v8Stage IVA Fallopian Tube Cancer AJCC v8Stage IVA Ovarian Cancer AJCC v8Stage IVA Primary Peritoneal Cancer AJCC v8Stage IVB Fallopian Tube Cancer AJCC v8Stage IVB Ovarian Cancer AJCC v8Stage IVB Primary Peritoneal Cancer AJCC v8Unresectable MelanomaUnresectable Ovarian CarcinomaUnresectable Synovial Sarcoma

Interventions

DRUG

Cyclophosphamide

Given IV

DRUG

Decitabine

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Leukapheresis

Undergo leukapheresis

BIOLOGICAL

TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes

Given IV

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Roswell Park Cancer Institute

OTHER